Satellos Reports Third Quarter 2026 Financial Results and Highlights Company Progress

Rhea-AI Summary

Satellos Bioscience (MSLE) reported a third-quarter net loss of $11.168 million while advancing its Phase 2 forazapadin clinical programs. Loss per share was $0.53, versus $0.39 a year earlier. Cash, cash equivalents and short-term investments totaled $53.0 million at September 30, 2026, versus $27.7 million at year-end 2025; the company expects funding to last through 2027.

BASECAMP completed enrollment of 53 boys with Duchenne muscular dystrophy. Its amended primary efficacy endpoint measures muscle fat fraction by MRI, with 12-week placebo-controlled topline data expected in Q1 2027. Satellos believes a potential accelerated approval pathway depends on supportive data and further FDA alignment. The company plans adult TRAILHEAD data by year-end 2026. U.S. and Canadian clearances allow evaluation in facioscapulohumeral muscular dystrophy, with TRAVERSE enrollment expected in Q1 2027.

11 points · 0 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 9 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Moderate point$53.0 million in cash and investments at September 30, 2026, versus $27.7 million at year-end 2025.
• Moderate point. Forward-looking: it has not happened yet and may not happen.Satellos expects its cash runway to extend through 2027.
• Moderate point. Forward-looking: it has not happened yet and may not happen.BASECAMP topline data from the 12-week placebo-controlled period are expected in Q1 2027.
• Minor pointBASECAMP enrollment completed with 53 ambulatory boys aged 7, 8 or 9 years.
• Minor point. Forward-looking: it has not happened yet and may not happen.TRAILHEAD 12-month data on four adult participants are planned by year-end 2026.

6 minor points

• Minor pointFDA and Health Canada clearances permit clinical evaluation of forazapadin in adults with facioscapulohumeral muscular dystrophy.
• Minor point. Forward-looking: it has not happened yet and may not happen.TRAVERSE start-up activities initiated; Satellos expects Phase 2 enrollment to begin in Q1 2027.
• Minor pointU.S. composition-of-matter patent granted for forazapadin and AAK1 inhibitors, expiring September 6, 2044.
• Minor pointQ3 finance income increased to $535,000 from $349,000 a year earlier.
• Minor pointNine-month finance income increased to $1.527 million from $1.104 million a year earlier.
• Minor pointQ3 foreign exchange gain was $12,000, versus a $185,000 loss a year earlier.

Negative

• Moderate pointQ3 net loss widened to $11.168 million, or $0.53 per share, from $5.821 million, or $0.39.
• Moderate pointQ3 research and development expenses increased to $8.998 million from $3.994 million a year earlier.
• Minor pointNine-month net loss widened to $32.654 million, or $1.62 per share, from $17.570 million, or $1.23.
• Minor pointNine-month research and development expenses increased to $25.943 million from $12.971 million a year earlier.
• Minor pointQ3 general and administrative expenses increased to $2.679 million from $1.972 million a year earlier.

4 minor points

• Minor pointNine-month general and administrative expenses increased to $7.942 million from $5.841 million a year earlier.
• Minor point. Forward-looking: it has not happened yet and may not happen.Potential accelerated approval pathway remains dependent on supportive clinical data and further FDA alignment.
• Minor pointTotal liabilities increased to $8.362 million at September 30, 2026, from $4.105 million at year-end 2025.
• Minor pointNine-month foreign exchange loss was $181,000, versus a $252,000 gain a year earlier.

News Explained

Satellos says the cash increase primarily reflects proceeds from an equity offering completed in February 2026, partly offset by cash used for operations; the higher balance therefore includes financing proceeds.

Key Figures

Cash, equivalents and short-term investments: $53.0 million Cash runway: Through 2027 BASECAMP enrollment: 53 ambulatory boys +5 more

Cash, equivalents and short-term investments

$53.0 million

As of Sept. 30, 2026; compared with $27.7 million at Dec. 31, 2025

Cash runway

Through 2027

Expected runway based on the company's stated financial position

BASECAMP enrollment

53 ambulatory boys

Phase 2 study in participants aged 7, 8 or 9 years

Placebo-controlled period

12 weeks

BASECAMP Phase 2 study

BASECAMP topline data timing

Q1 2027

Expected data from the 12-week placebo-controlled period

R&D expenses

$9.0 million

Quarter ended Sept. 30, 2026; compared with $4.0 million in the same 2025 quarter

Net loss

$11.2 million

Quarter ended Sept. 30, 2026; compared with $5.8 million in the same 2025 quarter

Loss per share

$0.53

Quarter ended Sept. 30, 2026; compared with $0.39 in the same 2025 quarter

Previous Earnings Reports

1 past event · Latest: Aug 13

Same Type 1 event

1. Aug 13

   Quarterly earnings

   24h Move

   -2.1%

   Reported a $11.7 million net loss, alongside positive trial findings and cash runway through 2027.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

mri, primary efficacy endpoint, accelerated approval pathway, investigational new drug application, +2 more

6 terms

mri technical

"selecting change in MRI-measured vastus lateralis fat fraction as the primary efficacy endpoint"

Magnetic resonance imaging (MRI) is a medical scan that uses magnetic fields and radio waves to create detailed pictures of the inside of the body, like a high-resolution camera for tissues and organs. Investors care because MRI drives demand for imaging machines, hospital services, diagnostics and can be central to clinical trial results and regulatory decisions—changes in MRI use or technology can affect revenue, capital spending and reimbursement in healthcare and medical device markets.

primary efficacy endpoint medical

"as the primary efficacy endpoint"

The primary efficacy endpoint is the single main result a clinical trial is designed to measure to decide whether a treatment works, chosen before the study starts. Think of it as the official scoreboard metric judges use to declare a win or loss; investors watch it because meeting or missing this pre-set goal usually drives regulatory approval odds, market expectations, and a company’s stock value.

accelerated approval pathway regulatory

"may support a potential accelerated approval pathway"

The accelerated approval pathway is a process that allows new medicines to be approved more quickly based on early evidence that they may be effective, rather than waiting for full proof. This can help patients access promising treatments faster, but it also means ongoing studies are needed to confirm the benefits. For investors, it highlights potential faster market entry and earlier revenue opportunities, along with some uncertainty about long-term outcomes.

investigational new drug application regulatory

"An Investigational New Drug Application (IND) and Clinical Trial Application (CTA)"

An investigational new drug application is a formal request made to regulatory authorities to begin testing a new medication in humans. It is a critical step in the drug development process, as approval indicates the drug has passed initial safety checks and can be studied further. For investors, this signals that a potential new treatment is progressing through its early testing stages, which can impact the company's future growth prospects.

clinical trial application regulatory

"Clinical Trial Application (CTA) have been cleared"

An application submitted to a regulatory authority requesting formal permission to begin testing a new drug, medical device, or treatment in humans. Like asking for a building permit before construction, it summarizes safety data, plans for how the study will be run, and monitoring procedures; investors watch these filings closely because approval lets a program move from lab research to clinical testing, reducing uncertainty and creating value-driving milestones.

process performance qualification technical

"process performance qualification (PPQ) activities"

Process Performance Qualification is the final proof stage where a manufacturer runs full-scale production under normal conditions to show the method consistently produces safe, effective, and high-quality products. For investors, it signals that manufacturing is reliable and compliant with regulators—reducing the risk of supply interruptions, costly recalls, or regulatory delays and helping predict production capacity and future revenue.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• BASECAMP Phase 2 topline data expected in Q1 2027 
• MRI-measured muscle fat fraction selected as the primary efficacy endpoint for BASECAMP
• Forazapadin cleared to begin clinical evaluation for FSHD in the U.S. and Canada; enrollment in Phase 2 TRAVERSE study expected to begin in Q1 2027
• Strong financial position with $53.0 million in cash, cash equivalents and short-term investments as of Sept. 30, 2026, expected to provide cash runway through 2027
  
  

TORONTO, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage company developing potentially life-improving medicines to treat degenerative muscle diseases, today announced financial results for the third quarter ended September 30, 2026. The company also provided an update on the clinical development of forazapadin, Satellos’ oral small molecule drug candidate designed to restore muscle regeneration in people living with Duchenne muscular dystrophy (DMD), facioscapulohumeral muscular dystrophy (FSHD) and potentially other muscle diseases.

“Our progress in the second half of 2026 reflects continued execution across our programs and brings us closer to important clinical and regulatory milestones,” said Frank Gleeson, Satellos co-founder and chief executive officer. “We are highly encouraged by our interactions with the FDA regarding the potential for an accelerated approval pathway of forazapadin in DMD and look forward to reporting topline data from BASECAMP, which we expect in the first quarter of next year. In parallel, we recently initiated start-up activities for our TRAVERSE study of forazapadin in FSHD and expect enrollment to begin in the first quarter of next year. We are also exploring opportunities to further extend our regenerative approach to other conditions where enhanced muscle regeneration could provide meaningful benefit.”

Data from BASECAMP Phase 2 pediatric study expected in Q1 2027
Enrollment has been completed for BASECAMP, a Phase 2 clinical trial evaluating forazapadin in 53 ambulatory boys with DMD aged 7, 8 or 9 years. Following interactions with the U.S. Food and Drug Administration (FDA), Satellos submitted an amended BASECAMP protocol selecting change in MRI-measured vastus lateralis fat fraction as the primary efficacy endpoint. Safety and tolerability remain primary objectives, with dynamometry and other clinical measures, including physical activity, function and biomarkers, being evaluated as secondary endpoints. Satellos believes that MRI fat fraction, together with clinical endpoints, may support a potential accelerated approval pathway for forazapadin, subject to supportive clinical data and further alignment with the FDA. Topline data from BASECAMP’s 12-week placebo-controlled period are expected in the first quarter of 2027.

Data from TRAILHEAD Phase 2 study in adults expected by the end of 2026
TRAILHEAD is a 12-month, open-label Phase 2 clinical trial designed to assess long-term safety, tolerability, efficacy and sustained functional benefit of forazapadin in adults with DMD. The company intends to report 12-month data by the end of 2026 on the four participants who transitioned from the Phase 1b study into TRAILHEAD.

Satellos to evaluate forazapadin in adults with FSHD
An Investigational New Drug Application (IND) and Clinical Trial Application (CTA) have been cleared by the U.S. FDA and Health Canada, respectively, allowing Satellos to begin clinical evaluation of forazapadin in adults with FSHD. The company has initiated start-up activities for its Phase 2 trial, known as “TRAVERSE” (NCT07872306), and expects to begin enrolling participants in the first quarter of 2027.

Additional third quarter business updates

• Satellos’ lead drug candidate, SAT-3247, was assigned “forazapadin,” as the International Nonproprietary Name, supporting its future development.
• Satellos was granted a composition of matter patent for forazapadin and adaptor-associated kinase 1 (AAK1) inhibitors by the U.S. Patent and Trademark Office, with an expiration date of Sept. 6, 2044.
• The company established a scientific advisory board of internationally recognized leaders in stem cell biology, regenerative medicine, neuroscience and small molecule chemistry who will help guide the company's long-term scientific exploration of regeneration, aging and neurodegenerative biology.
  
  

Third quarter 2026 financial results

• Cash Position: Satellos had cash, cash equivalents and short-term investments of $53.0 million as of Sept. 30, 2026, compared with $27.7 million on December 31, 2025. The increase primarily reflects proceeds from an equity offering completed in February 2026, partially offset by cash used to fund ongoing operations.
• R&D Expenses: Research and Development expenses increased to $9.0 million for the quarter ended Sept. 30, 2026, compared to $4.0 million for the quarter ended Sept. 30, 2025. The increase was primarily due to costs associated with the TRAILHEAD and BASECAMP clinical studies, as well as chemistry and manufacturing control (CMC) costs related to drug production and process performance qualification (PPQ) activities to support the clinical studies and begin commercial GMP preparations for a potential future NDA filing.
• G&A Expenses: General and Administrative expenses increased to $2.7 million for the quarter ended Sept. 30, 2026, as compared to $2.0 million for the quarter ended Sept. 30, 2025, primarily due to increased headcount and professional fees associated with public company reporting obligations.
• Net Loss: For the quarter ended Sept. 30, 2026, the company reported a net loss of $11.2 million ($0.53 loss per share), compared to a net loss of $5.8 million ($0.39 loss per share) for the quarter ended Sept. 30, 2025.
  
  

Satellos' financial statements for the quarter ended Sept. 30, 2026, and the related management's discussion and analysis (MD&A) are available on the Company website (satellos.com), EDGAR (sec.gov), and SEDAR+ (sedarplus.ca).

ABOUT FORAZAPADIN
Forazapadin is a proprietary, oral small molecule drug candidate being developed by Satellos as a novel approach to regenerating skeletal muscle lost in degenerative muscle diseases or injury conditions. Forazapadin targets AAK1, a key protein identified by Satellos as a potential target for restoring the body’s natural muscle repair and regeneration biology, a fundamental process that is disrupted in DMD, FSHD and other degenerative conditions. By inhibiting AAK1, forazapadin treatment aims to re-establish a biochemical signal believed to be involved in supporting muscle regeneration. Satellos is advancing forazapadin as a potential treatment for DMD that is independent of dystrophin and applicable regardless of exon mutation status as either a stand-alone or adjunctive therapy. The company is also evaluating forazapadin as a genetic-mutation independent approach to FSHD.

ABOUT SATELLOS BIOSCIENCE INC.
Satellos is a clinical-stage drug development company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, Satellos has developed forazapadin, an orally administered small molecule AAK1 inhibitor designed to address deficits in muscle repair and regeneration. Forazapadin is being evaluated as a potential disease-modifying treatment for DMD in two Phase 2 clinical trials, BASECAMP in pediatric participants with DMD and TRAILHEAD in adults living with DMD. The company is also evaluating forazapadin in TRAVERSE, a Phase 2 clinical study in adults with FSHD. The company has identified additional muscle diseases and injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and plans to pursue these opportunities in future clinical development. For more information, visit www.satellos.com and connect with Satellos on X, LinkedIn, Facebook and Instagram.

NOTICE ON FORWARD-LOOKING STATEMENTS
This press release includes forward-looking information or forward-looking statements within the meaning of applicable securities laws regarding Satellos and its business, which may include, but are not limited to, statements regarding the therapeutic potential of forazapadin, including its potential to represent a disease-modifying approach to the therapeutic treatment of people living with DMD and as a dystrophin-independent treatment for DMD enrollment in, advancement and timing of results of forazapadin through clinical trials, including the BASECAMP, TRAILHEAD and TRAVERSE clinical trials; the potential for an accelerated approval pathway of forazapadin in DMD and the potential use of MRI-measured muscle fat fraction in support thereof; the potential of Satellos’ approach in other degenerative muscle diseases and Satellos’ plans to pursue additional muscle diseases and injury conditions in future clinical development; forazapadin's prospective impact on DMD and FSHD patients, patients with other degenerative muscle disease or muscle injury or trauma, and on muscle regeneration generally the anticipated timing for BASECAMP and TRAILHEAD Phase 2 data; and its expectations regarding the sufficiency of its cash, cash equivalents and short-term investments to fund operations through 2027. All statements that are, or information which is, not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, occurrences or developments, are “forward-looking information or statements.” Often, but not always, forward-looking information or statements can be identified by the use of words such as “shall”, “intends”, “believe”, “plan”, “expect”, “intend”, “estimate”, “anticipate”, “potential”, “prospective”, “assert” or any variations (including negative or plural variations) of such words and phrases, or state that certain actions, events or results “may”, “might”, “can”, “could”, “would” or “will” be taken, occur, lead to, result in, or, be achieved. Such statements are based on the current expectations and views of future events of the management of Satellos. These statements are based on assumptions and subject to risks and uncertainties. In making forward looking statements, Satellos has relied on various assumptions, including but not limited to: its ability to obtain future funding on favorable terms, if at all; its ability to obtain positive results in its clinical trials; its ability to obtain necessary regulatory approvals; its ability to arrange for the manufacturing of its product candidates and technologies; its clinical trials proceeding in accordance with anticipated timelines; and general business, market and economic conditions. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting Satellos, including, without limitation, risks relating to the pharmaceutical and bioscience industry (including the risks associated with preclinical and clinical trials and regulatory approvals), the research and development of therapeutics, the results of preclinical and clinical trials, general market conditions and equity markets, economic factors and management's ability to manage and to operate the business of Satellos generally, including inflation and the costs of operating a biopharma business, and those risks and uncertainties described in more detail in the “Risk Factors” section of Satellos' Annual Information Form dated March 27, 2026, and amended and restated short form base shelf prospectus dated August 11, 2026 (each of which is located on Satellos' SEDAR+ profile) and incorporated by reference in Satellos’ Form F-10 filed with the Securities and Exchange Commission on August 11, 2026, and in Satellos' public filings on EDGAR (sec.gov) and SEDAR+ (sedarplus.ca). Although Satellos has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Satellos does not undertake any obligation to publicly update or revise any forward-looking statement, whether resulting from new information, future events, or otherwise.

CONTACTS
Investors: Caitlin Lowie, Vice President, Investor Relations & Communications, ir@satellos.com
Media: Emily Williams, Senior Director, Communications, media@satellos.com

SATELLOS BIOSCIENCE INC. Condensed Consolidated Interim Statements of Financial Position (Expressed in thousands of US Dollars) (Unaudited)
As at,	Notes	September 30, 2026			December 31, 2025
		$			$
ASSETS
Current
Cash and cash equivalents	3	6,175			9,804
Short-term investments	4	46,839			17,906
Sales tax, interest and other receivables		923			370
Prepaid expenses, deposits and other current assets	5	4,042			3,804
Total current assets		57,979			31,884
Property and equipment		6			5
TOTAL ASSETS		57,985			31,889
LIABILITIES
Accounts payable and accrued liabilities	6	7,748			4,105
Deferred contribution liability	7	614			-
Total current liabilities		8,362			4,105
Total Liabilities		8,362			4,105
SHAREHOLDERS’ EQUITY
Common Shares	8	135,443			85,828
Pre-Funded Warrants	8	17,834			15,480
Contributed surplus		12,664			10,166
Accumulated deficit		(114,624	)		(81,970	)
Accumulated other comprehensive loss		(1,694	)		(1,720	)
Total shareholders’ equity		49,623			27,784
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY		57,985			31,889

SATELLOS BIOSCIENCE INC. Condensed Consolidated Interim Statements of Loss and Comprehensive Loss (Expressed in thousands of US Dollars, except for per share amounts) (Unaudited)
		Three months ended September 30,						Nine months ended September 30,
	Notes	2026 $			2025 $			2026 $			2025 $
Research and development (“R&D”)	7,11	8,998			3,994			25,943			12,971
General and administrative (“G&A”)	11	2,679			1,972			7,942			5,841
TOTAL R&D AND G&A EXPENSES		(11,677	)		(5,966	)		(33,885	)		(18,812	)
OTHER INCOME AND EXPENSES
Finance income		535			349			1,527			1,104
Foreign exchange gain/(loss)		12			(185	)		(181	)		252
NET LOSS BEFORE INCOME TAXES		(11,130	)		(5,802	)		(32,539	)		(17,456	)
Income taxes		(38	)		(19	)		(115	)		(114	)
NET LOSS FOR THE PERIOD		(11,168	)		(5,821	)		(32,654	)		(17,570	)
OTHER COMPREHENSIVE LOSS
Items that may be reclassified to net loss
Foreign currency translation adjustments		3			-			26			62
TOTAL COMPREHENSIVE LOSS		(11,165	)		(5,821	)		(32,628	)		(17,508	)
Basic and diluted loss per Common Share	8	$(0.53	)		$(0.39	)		$(1.62	)		$(1.23	)
Basic and diluted loss per Pre-Funded Warrant	8	$0.00			$0.00			$0.00			$0.00
Weighted average number of Common Shares	8	21,183,573			14,818,699			20,161,575			14,305,774

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Satellos report BASECAMP Phase 2 results?

Satellos expects topline data in Q1 2027 from BASECAMP’s 12-week placebo-controlled period. Enrollment is complete with 53 ambulatory boys with Duchenne muscular dystrophy aged 7, 8 or 9 years.

What is the new primary efficacy endpoint in Satellos’ BASECAMP trial?

The amended BASECAMP protocol selects change in MRI-measured vastus lateralis fat fraction as the primary efficacy endpoint. Safety and tolerability remain primary objectives. Secondary endpoints include dynamometry, a measure of muscle strength, along with physical activity, function and biomarkers.

Why did Satellos’ third-quarter 2026 research and administrative expenses increase?

Higher research spending primarily reflected TRAILHEAD and BASECAMP study costs and drug-production and manufacturing-preparation activities. Those activities support clinical studies and begin commercial manufacturing preparations for a potential future drug application. Administrative expenses increased primarily because of higher headcount and professional fees associated with public-company reporting obligations.